Affiliation: Fox Chase Cancer Center
- Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumoursL P Martin
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Br J Cancer 107:1268-76. 2012..This phase I study investigated the safety, tolerability, pharmacokinetics and antitumour activity of axitinib combined with chemotherapy...
- Novel non-cytotoxic therapy in ovarian cancer: current status and future prospectsLainie Martin
From Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19103, USA
J Natl Compr Canc Netw 4:955-66. 2006..This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment...
- Development of a syngeneic mouse model of epithelial ovarian cancerBridget A Quinn
Women s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
J Ovarian Res 3:24. 2010..The objective of this study was to establish an immunocompetent syngeneic mouse model of disseminated epithelial ovarian cancer (EOC) to facilitate laboratory-based studies of ovarian tumor biology and preclinical therapeutic strategies...
- Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibitionLainie Martin
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 25:2894-901. 2007..Current data regarding the role of bevacizumab and other novel agents in the treatment of ovarian carcinoma are summarized...